Proteome-derived Peptide Libraries Allow Detailed Analysis of the Substrate Specificities of Nα-acetyltransferases and Point to hNaa10p as the Post-translational Actin Nα-acetyltransferase*

Petra Van Damme‡§¶¶, Rune Evjenth¶¶, Håvard Foyn¶¶¶, Kimberly Demeyer‡§, Pieter-Jan De Bock‡§, Johan R. Lillehaug¶¶, Joël Vandekerckhove‡§, Thomas Arnesen¶¶¶¶, and Kris Gevaert‡§**‡‡

The impact of N-terminal acetylation on protein stability and protein function in general recently acquired renewed and increasing attention. Although the substrate specificity profile of the conserved enzymes responsible for N-terminal acetylation in yeast has been well documented, the lack of higher eukaryotic models has hampered the specificity profile determination of Nα-acetyltransferases (NATs) of higher eukaryotes. The fact that several types of protein N termini are acetylated by so far unknown NATs stresses the importance of developing tools for analyzing NAT specificities. Here, we report on a method that implicates the use of natural, proteome-derived modified peptide libraries, which, when used in combination with two strong cation exchange separation steps, allows for the delineation of the in vitro specificity profiles of NATs. The human NatA complex, composed of the auxiliary hNaa15p (NATH/hNat1) subunit and the catalytic hNaa10p (hArd1) and hNaa50p (hNat5) subunits, cotranslationally acetylates protein N termini initiating with Ser, Ala, Thr, Val, and Gly following the removal of the initial Met. In our studies, purified hNaa50p preferred Met-Xaa starting N termini (Xaa mainly being a hydrophobic amino acid) in agreement with previous data. Surprisingly, purified hNaa10p preferred acidic N termini, representing a group of in vivo acetylated proteins for which there are currently no NAT(s) identified. The most prominent representatives of the group of acidic N termini are γ- and β-actin. Indeed, by using an independent quantitative assay, hNaa10p strongly acetylated peptides representing the N termini of both γ- and β-actin, and only to a lesser extent, its previously characterized substrate motifs. The immunoprecipitated NatA complex also acetylated the actin N termini efficiently, though displaying a strong shift in specificity toward its known Ser-starting type of substrates. Thus, complex formation of NatA might alter the substrate specificity profile as compared with its isolated catalytic subunits, and, furthermore, NatA or hNaa10p may function as a post-translational actin Nα-acetyltransferase. Molecular & Cellular Proteomics 10.1074/mcp.M110.004580, 1–12, 2011.

The multisubunit and ribosome-associated protein Nα-acetyltransferases (NATs)1 are omnipresent enzyme complexes that catalyze the transfer of the acetyl moiety from acetyl-CoA to the primary α-amines of N termini of nascent proteins (1–3). As up to 50 to 60% of yeast proteins and 80 to 90% of human proteins are modified in this manner, Nα-acetylation is a widespread protein modification in eukaryotes (4–7), and the pattern of modification has remained largely conserved throughout evolution (4, 8). NATs belong to a subfamily of the Gcn5-related N-acetyltransferase superfamily of N-acetyltransferases, additionally encompassing the well-studied histone acetyltransferases that are implicated in epigenetic imprinting.

In yeast and humans, three main NAT complexes, NatA, NatB, and NatC were found to be responsible for the majority of Nα-terminal acetylations (1). The NatA complex, responsible for cotranslational Nα-terminal acetylation of proteins with Ser, Ala, Thr, Gly, and Val N termini, is composed of two main subunits, the catalytic subunit Naa10p (previously known as Ard1p) and the auxiliary subunit Naa15p (previously known as Nat1p/NATH) (9–11). Furthermore, a third catalytic subunit

1 The abbreviations used are: NAT, Nα-acetyltransferase; Ac(D3), (trideutero)-acetyl; Ard1, arrest-defective 1 protein; CoA, Coenzyme A; NAA#, N-alpha acetyltransferase # (gene/protein); NATH, N-acetyltransferase human; pGAPase, pyroglutamyl aminopeptidase; SCX, strong cation exchange; FPLC, fast protein liquid chromatography.
Naa50p (previously known as Nat5)—an acetyltransferase shown to function in chromosome cohesion and segregation (12–14)—was found to physically interact with the NatA complex of yeast (2), fruit fly (12), and human (15). Recently, human Naa50p (hNaa50p) was reported to display lysine or N^\text{\textsuperscript{o}}-acetyltransferase as well as NAT activity (16), the latter was defined as NatE activity (16). Interestingly, the chaperone-like, Huntingtin interacting protein HYPK, identified as a novel stable interactor of human NatA, was functionally implicated in the N-terminal acetylation of an in vivo NatA substrate, demonstrating that NAT complex formation and composition may have a general influence on the observed (degree of) N^\text{\textsuperscript{o}}-acetylation (17). Further, subunits of the human NatA complex have been coupled to cancer-related processes and differentiation, with altered subunit expression reported in papillary thyroid carcinoma, neuroblastoma, and retinoic acid induced differentiation. Furthermore, the NatA catalytic subunit was found to be implicated in processes such as hypoxia-response and the β-catenin pathway (18, 19). Of note is that in line with the differential localization patterns of the individual NatA subunits (9, 13, 20, 21), other data indicate that these subunits might well exert NatA-independent enzymatic functions (13, 22, 23). Given that a significant fraction of hNaa10p and hNaa15p are nonribosomal (9), and given the multitude of postulated post-translational in vivo N-acetylation events recently reported (24–26), these observations argue in favor of the existence of NAT complexes and/or catalytic NAT-subunits acting post-translationally.

Similar to NatA, the NatB and NatC complexes, composed of the catalytic subunit Naa20p or Naa30p and the auxiliary subunits Naa25p or Naa35p and Naa38p respectively, are conserved from yeast to higher eukaryotes concerning their physiological roles of NATs in the normal and the disease state.

The specificity of N^\text{\textsuperscript{o}}-acetyltransferases and their endogenous substrates were originally studied by two-dimensional-PAGE: N^\text{\textsuperscript{o}}-acetylation neutralizes the N-terminal positive charge, resulting in an altered electrophoretic protein migration during isoelectric focusing (35–38). Recently, this altered biophysical property was also exploited to enrich for protein N-termini using low pH strong cation exchange (SCX) chromatography (24, 39). As an example, SCX prefractionation combined with N-terminal combined fractional diagonal chromatography, a targeted proteomics technology negatively selecting for protein N-terminal peptides, stable isotope labeling of amino acids in cell culture, and amino-directed modifiers (40), was used to study the in vivo substrate repertoires of human as well as yeast NatA (4).

Nevertheless, the various methods reported today to study in detail N-terminal acetylation and thus the specificities of different NATs make use of a limited and therefore somewhat biased set of synthesized peptide substrates and comprise the rather laborious detection of radioactive acetylated products as well as enzyme-coupled methods quantifying acetyl-CoA conversion. Because (proteome-derived) peptide libraries have been used extensively to study epitope mapping (41), protein–protein interactions (42), protein modifications such as phosphorylation (43), and proteolysis (44, 45), as well as for determining the substrate specificity of the N^\text{\textsuperscript{o}}-deblocking peptide deformylase (46), we reckon that the development of an oligopeptide-based acetylation assay should allow for more comprehensive screening of NAT-like activities. We here report on the development of a peptide-based method to systematically screen for the in vitro sequence specificity profile of individual NATs as well as endogenous NAT complexes. In summary, SCX enriched, N^\text{\textsuperscript{o}}-free peptide libraries, derived from natural proteomes build up the peptide substrate pool. And, upon incubation, NAT N^\text{\textsuperscript{o}}-acylated peptides are enriched by a second SCX fractionation step, resulting in a positive selection of NAT-specific peptide substrates. By use of this proteome-derived peptide library approach, we here...
delineated (differences in) the specificity profiles of hNaa50p and hNaa10p as isolated hNatA components, as well as of assayed their combined activity when in their native hNatA complex.

EXPERIMENTAL PROCEDURES

Cell Culture—Human K-562 cells were from the ATCC (CCL-243, American Type Culture Collection, Manassas, VA, USA) and were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA), 100 units/ml penicillin (Invitrogen), and 100 μg/ml streptomycin (Invitrogen). Human A-431 cells (ATCC, CL-1555) were grown in Dulbecco’s modified Eagle’s medium supplemented with 2 mM L-glutamine, 50 mg/ml gentamicin, and 10% newborn calf serum (Lonzza Group, Basel, Switzerland). Cells were cultured at 37 °C and in 5% CO2.

Preparation of Proteome-derived Peptide Libraries—Proteome-derived peptide libraries were generated from human K-562 cells. Cells were repeatedly (3×) washed in ρH phosphate-buffered saline and then re-suspended at 7×106 cells per ml in lysis buffer (50 mM sodium phosphate buffer pH 7.5, 100 mM NaCl, 1% 3-[3-cholamidopropyl]dimethylammonio]-1-propanesulfonic acid (CHAPS), and 0.5 mM EDTA) in the presence of protease inhibitors (Complete protease inhibitor mixture tablet (Roche Diagnostics, Mannheim, Germany)). Following lysis for 10 min on ice, the lysate was cleared by centrifugation for 10 min at 16,000×g and then solid guanidinium hydrochloride was added to the supernatant to a final concentration of 4 M. The sample was acidified to pH 3.0 using a stock solution of 1% trifluoroacetic acid (TFA) in 50% acetonitrile and further diluted with 10 mM sodium phosphate in 50% acetonitrile to a final volume of 1 ml. This peptide mixture was then loaded onto an AccuBondII SCX SPE cartridge (Agilent Technologies, Waldbronn, Germany) and SCX separation (SCX fractionation 1) of N*-blocked N-terminal peptides and C-terminal peptides from N*-free peptides was performed as described previously (39, 47). The resulting peptide mixtures were vacuum dried. The dried peptides were redissolved in 500 μl 50% acetonitrile. The sample was acidified to pH 3.0 using a stock solution of 1% trifluoroacetic acid (TFA) in 50% acetonitrile and further diluted with 10 mM sodium phosphate in 50% acetonitrile to a final volume of 1 ml. This peptide mixture was then loaded onto an AccuBondII SCX SPE cartridge (Agilent Technologies, Waldbronn, Germany) and SCX separation (SCX fractionation 1) of N*-blocked N-terminal peptides and C-terminal peptides from N*-free peptides was performed as described previously (39, 47). The flow-through containing the N*-blocked N-terminal peptides and C-terminal peptides was discarded and the SCX-bound fraction (containing the N*-free peptides) was collected by elution with 4 ml of 400 mM NaCl and 10 mM sodium phosphate in 40% of acetonitrile (pH 3.0). Eluted peptides were vacuum dried and redissolved in 1 ml of high performance liquid chromatography (HPLC) solvent A (10 mM ammonium acetate in 2% acetonitrile, pH 5.5). C18 solid-phase extraction (SPE desalting step) of the N*-free peptides was performed by loading the peptide mixture onto an AccuBondII ODS-C18 SPE cartridge (1 ml tube, 100 mg, Agilent Technologies, Santa Clara, CA). This cartridge has a binding capacity of 1 mg of peptides and thus for each milligram of material, a separate cartridge was used. Prior to sample loading, the cartridges were washed with 2 ml of 50% acetonitrile and then washed with 5 ml of HPLC solvent A. Sample loading was followed by washing the C18 cartridge with 5 ml of 2% acetonitrile. Peptides were eluted with 3 ml of 70% acetonitrile and subsequently vacuum dried.

In Vitro Peptide Library-based NAT Assay—One hundred nanomolar of the desalted N*-free peptide pool was reconstituted in acetylation buffer (50 mM Tris-Cl pH (8.5), 1 mM dithiothreitol, 800 μM EDTA, 10% glycerol) and equimolar amounts of a stable isotope encoded variant of acetyl-CoA, 13C2-acetyl CoA, (99% 13C2-acetyl CoA, ISOTEC-Sigma (lithium salt)) and the indicated amount of enzyme was added to a final reaction volume of 1 ml. The reaction was allowed to proceed for 1 h (for the recombinant enzymes) or 2 h (for the immunoprecipitated complexes) at 37 °C and stopped by addition of acetic acid to a 5% final concentration. SPE was then performed as described above.

NAT Oligopeptide-substrate Recovery and Reverse Phase (RP)-HPLC-based Separation—Peptides starting with pyrogulamate were unblocked prior to the second SCX fractionation step. Here, 25 μl of pGAPase (25 U/ml) (TAGzyme kit, Qiagen, Hilden, Germany) was activated for 10 min at 37 °C by addition of 1 μl of 50 mM EDTA (pH 8.0), 1 μl of 800 mM NaCl, and 11 μl of freshly prepared 50 mM cysteamine-HCl. Twenty-five microliters of Qcyclase (50 U/ml, TAGzymeTM) was then added to the pGAPase solution. The dried peptides were re-dissolved in 212 μl of buffer containing 16 mM NaCl, 0.5 mM EDTA, 3 mM cysteamine, and 50 μM aprotinin. The activated pGAPase and Q-cyclase mixture was added to the peptide sample and the mixture (275 μl total volume) was incubated for 60 min at 37 °C. Two hundred and seventy-five microliters acetonitrile was then added and the sample was acidified to pH 3 using a 1% TFA stock solution in 50% acetonitrile. The sample was further diluted with 10 mM sodium phosphate in 50% acetonitrile to a final volume of 1 ml. SCX enrichment of N*-blocked N-terminal peptides was performed as described previously (39) (SCX fractionation 2). The SCX fraction containing the newly blocked N-terminal peptides was vacuum dried and re-dissolved in 100 μl of HPLC solvent A. To prevent oxidation of methionine between the primary and secondary RP-HPLC separations (and thus unwanted segregation of methionyl peptides (49)), methionines were uniformly oxidized to sulfoxides prior to the primary RP-HPLC run by adding 2 μl of 30% (w/v) H2O2 (final concentration of 0.06%) for 30 min at 30 °C. This peptide mixture was injected onto a RP-column (Zorbax® 300SB-C18 Narrowbore, 2.1 mm (internal diameter) x 150 mm length, 5 μm particles, Agilent Technologies) and the RP-HPLC separation was performed as described previously (39). Fractions of 30 s wide were collected from 20 to 80 min following sample injection (120 fractions). To reduce liquid chromatography (LC)-tandem MS (MS/MS) analysis time, fractions eluting 12 min apart were pooled, vacuum dried and re-dissolved in 40 μl of 2% acetonitrile. In total, 24 pooled fractions per setup were subjected to LC-MS/MS analysis (see below).

LC-MS/MS Analysis—LC-MS/MS analysis was performed using an Ultimate 3000 HPLC system (Dionex, Amsterdam, The Netherlands) in-line connected to a LTQ Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany) and, per LC-MS/MS analysis, 2 μl of sample was consumed. LC-MS/MS analysis and generation of MS/MS peak lists were performed as described (50). These MS/MS peak lists were then searched with Mascot using the Mascot Daemon interface (version 2.2.0, Matrix Science). The Mascot search parameters were set as follows. Searches were performed in the Swiss-Prot database with taxonomy set to human (UniProtKB/SwissProt database version 2010.05 of 20-Apr-2010 containing 20,286 human protein sequences). Trideuteracetyl-acylation at lysines, carbamidomethyl-acylation of cysteine and methionine oxidation to methionine-sulfoxide were set as fixed modifications. Variable modifications were trideuter-acylation, acetylation, and 13C2-acylation of protein N termini and pyrogulamate formation of N-terminal glutamine. Endoprotei-
nase Arg-C/P (Arg-C specificity with arginine-proline cleavage allowed) was set as enzyme allowing no missed cleavages. The mass tolerance on the precursor ion was set to 10 ppm and on fragment ions to 0.5 Da. Only MS/MS-spectra and corresponding identifications that exceeded the corresponding MASCOT’s threshold score of identity (at 95% confidence level) and that were ranked one, were withheld. The false discovery rate was estimated according to the method described by Käll et al. (51), and was found ≤2% at the spectrum level and ≤3% at the peptide level. Identified MS/MS spectra are made publicly available in the Proteomics Identification Database (PRIDE) (74) under the accession codes 13643, 13644, and 13645.
Delineating the Specificity Profile of \( N^\alpha \)-acetyltransferases

**Plasmid Construction, Protein Expression, and Purification**—The cDNA encoding hNaa10p and hNaa50p ORFs were cloned into pETM-41 [MBP (Maltose Binding Protein)/His-fusion] and pETM-30 (GST/His-fusion, generously provided by G. Stier, EMBL, Heidelberg, Germany) for expression in \( E. \ coli \). Correct cloning was verified by DNA sequencing and the plasmids were transformed into \( E. \ coli \) BL21 Star\textsuperscript{TM} (DE3) cells (Invitrogen) by heat shock. Two hundred milliliter cell cultures were grown in LB (Luria Bertani) medium to an OD\textsubscript{600 nm} of 0.6 at 37 °C and subsequently transferred to 20 °C. Following 30 min of incubation, protein expression was induced by IPTG (1 mM). Following 17 h of incubation, the cultures were harvested by centrifugation and the pellets stored at −20 °C. \( E. \ coli \) pellets containing recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM recombinant proteins were thawed at 4 °C and the cells lysed by sonication and french press in lysis buffer (1 mM dithiotreitol, 50 mM reco

**Immunoprecipitation of NAT Complexes**—An aliquot of 5 \( \times 10^6 \) A-431 cells (per sample) were harvested and lysed in 500 \( \mu \)l of lysis buffer (50 mM Tris (pH 8), 50 mM NaCl, 0.5% Nonidet P-40, 5 mM EDTA, 1 mM Pefabloc (Roche)). A total of 50 \( \mu \)l of protein A/G agarose (Santa Cruz) was added to the lysates and incubated for 1 h at 4 °C. Following centrifugation at 2000 \( \times \) g for 2 min, the supernatants were collected and incubated for another 2 h at 4 °C with 3 \( \mu \)g anti-hNaa15p (anti-NATH in (9)) or custom-made unspecific rabbit IgG (Biogenes). The samples were centrifuged as above and 50 \( \mu \)l of Protein A/G agarose was added to the supernatants. Following incubation for 16 h, three repetitive rounds of centrifugation and washing (two times in lysis buffer and once in acetylation buffer), the samples were used for an in vitro peptide acetylation assay.

**In Vitro N-Acetyltransferase Assay Using Synthetic Peptides**—Purified MBP-hNaa10p (40 nm) or GST-hNaa50p (50 nm) was mixed with selected oligopeptide substrates (200 \( \mu \)M) and 500 \( \mu \)M of acetyl-CoA in a total volume of 60 \( \mu \)l acetylation buffer. For MBP-hNaa10p, the samples were incubated at 37 °C for 10 min, whereas for GST-hNaa50p, the samples were incubated at 37 °C for 30 min. The enzyme activities were quenched by adding 5 \( \mu \)l of 10% TFA. The acetylation reactions were quantified using RP-HPLC as described previously (18). When making use of immunoprecipitated material as enzyme input, the assay was carried out the same way using a 60 min incubation time. In order to determine the concentration of the NatA complex used in the assays, we analyzed the immunoprecipitated NatA complex by SDS-PAGE and SYPRO Ruby (BioRad) staining. The relative intensities of hNaa10p, hNaa15p, and hNaa50p were quantified and compared with purified recombinant proteins and each other using Image Gauge V 4.0 and further corrected for the staining intensities contributed by the different protein species based on amino acid composition (52). This semi-quantitative analysis suggested that the complex is present in a 1:1:1 (1:0.96:0.87) stoichiometry and furthermore that one sample of immunoprecipitated NatA complex contained 0.4 pmol NatA (hNaa10p). Time course analysis of the different enzymes was performed to investigate initial velocity conditions (supplemental Fig. S1).

**Synthetic Peptide Sequences**—Peptides (supplemental Table 1) were custom-made (Biogenes) to a purity of 80%−95%. All peptides contain seven unique amino acids at their N terminus, as these are the major determinants influencing N-terminal acetylation. The next 17 amino acids are essentially identical to the adrenocorticotrophic hormone peptide sequence (RWGRPGRRRPVRVYP) however, lysines were replaced by arginines to minimize any potential interference by \( N^\alpha \)-acetylation.

** Gel Filtration Assay**—A cell pellet from \( \sim 2 \times 10^7 \) A-431 cells was resuspended in homogenization buffer (0.25 M Sucrose, 140 mM NaCl, 1 mM EDTA, 1 mM Pefabloc (Roche), 20 mM Tris-HCl pH 8.0) and homogenized using a cell-cracker (EMBL Germany) using six strokes with a 4 \( \mu \)m gap. Following centrifugation at 17,000 \( \times \) g for 20 min, 500 \( \mu \)l of clear cell lysate (supernatant) was applied on a Superdex 200 10/300 GL (GE Healthcare) gel filtration column. The column was pre-equilibrated with 50 mM Tris-HCl (pH 8.0), 200 mM NaCl and 10% glycerol using settings as recommended by the manufacturer. Two hundred and fifty microliter fractions were collected and analyzed by SDS-PAGE and Western blotting using anti-hNaa10p and anti-hNaa15p.

**Ribosome Isolation**—Approximately \( 2 \times 10^7 \) HEK293 cells were used per experiment. Prior to harvesting, cells were treated with 10 \( \mu \)g/ml cycloheximide for 5 min at 37 °C. Cells were harvested, lysed with KCl-containing ribosome lysis buffer (1.1% (w/v) KCl, 0.15% (w/v) triethanolamine, 0.1% (w/v) magnesium acetate, 8.6% (w/v) sucrose, 0.05% (w/v) sodium deoxycholate, 0.5% (w/v) Triton-X100, 0.25% (w/v) Pefabloc) and incubated on ice for 15 min. Following removing the nuclear and membrane containing fraction by centrifugation at 400 \( \times \) g for 10 min, 700 \( \mu \)l cell lysate was ultra-centrifuged at 436,000 \( \times \) g for 25 min on a 0.4 ml cushion of 25% sucrose in KCl ribosome lysis buffer using a MLA-130 rotor (Beckman, Geneva, Switzerland). Pellets were resuspended in ribosome lysis buffer with the indicated KCl concentrations, followed by ultracentrifugation as described above. Pellets were resuspended in KCl ribosome lysis buffer, and prepared for analysis by SDS-PAGE and Western blotting.

**RESULTS**

**Proteome-derived Peptide Library Generation and Isolation of NAT-specific Peptide Substrates**—The proteome-derived peptide library generation workflow and NAT-substrate isolation assay is shown in Fig. 1. At the protein level, cysteine sulphydryls are protected by carbamidomethylation and primary amines are modified by trideuterated-acetylation. This primary amine protection step, besides being a prerequisite for the applied selection strategy (see below), additionally excludes nonenzymatic acetyl-CoA modification, which was reported to occur spontaneously on \( N^\alpha \)-amines of lysine side chains (53). Subsequently, the modified protein mixture is digested with trypsin, resulting in the formation of endoproteinase Arg-C type of peptides (because trypsin will not cleave at trideuterated-acetylated lysines). To create a peptide library that is mainly composed of \( N^\alpha \)-free peptides and thus to generate a large substrate pool for NATs, the naturally acetylated and the in vitro blocked (trideuterated-acetylated) N-terminal peptides are removed from this modified peptide pool by a first round of SCX separation at pH 3.0. Here, the flow-through, or SCX nonretained fraction composed of peptides with an overall net charge of zero and thus containing the \( N^\alpha \)-blocked peptides (39), is discarded and a high-salt elution step is applied to recover the SCX-resin bound, \( N^\alpha \)-free peptide fraction. Before incubation with the NAT of interest, the recovered peptides are further purified by solid-phase extraction.

10.1074/mcp.M110.004580-4
Following purification, the desalted N\textsuperscript{\textast}}-free-peptide library is dissolved in a NAT compatible buffer and incubated with the acetyl donor acetyl-CoA and a purified NAT enzyme or NAT complex of interest. In order to distinguish between possibly copurified \textit{in vivo} or \textit{in vitro} N\textsuperscript{\textast}}-acylated/trideuterated background peptides and enzymatic \textit{in vitro} NAT-N\textsuperscript{\textast}}-acylated peptides, an isotopic, and thus MS-distinguishable variant of acetyl-CoA, 1,2\textsuperscript{13}C\textsubscript{2}-acetyl-CoA, is used as acetyl donor. Enzymatically acetylated peptides are then isolated by a second SCX fractionation step as described above, but now remaining glutamine-starting peptides are removed prior to the second SCX fractionation step to avoid having pyroglutamate peptides co-enriched with acetylated peptides. We only implemented this step prior to the second SCX fractionation step as we wanted Gln-starting peptides to serve as potential oligopeptide substrates for the NATs assayed. In general, following completion of the isolation protocol, only 2\% pyroglutamate peptides remained, all of which held proline as the second amino acid, which is expected given that this residue is refractory to pGAPase activity (39). As such, and because spontaneous N\textsuperscript{\textast}}-acylation is not observed, mainly enzymatically N\textsuperscript{\textast}}-acylated peptides are found in the flow-through fraction of this second low pH SCX fractionation step. Following LC-MS/MS analysis, the NAT substrate peptides identified were used to determine the sequence specificity of the studied NAT (see below).

The Specificity Profile of Recombinant hNaa50p—Because N\textsuperscript{\textast}}-acylation activity of recombinant hNaa50p has been shown to target various Met-starting peptides (16), our approach was first challenged using recombinant hNaa50p. hNaa50p N-terminally fused to maltose-binding protein was expressed in \textit{E. coli}, purified, and incubated with a proteome-derived peptide library from human cells. The enzyme-treated peptide library was then processed as described above. Following LC-MS/MS analysis of the second SCX flow-through fraction, 3602 MS/MS spectra linked to 1860 peptides were identified. Of these, 1342 peptides (72\%) were enzymatically,
in vitro N\(^\text{\textsuperscript{13}}\)C\(_2\)-acetylated. Other peptides were either incompletely retained N\(^\text{\textsuperscript{3}}\)-free peptides (444 peptides) or otherwise N\(^\text{\textsuperscript{3}}\)-blocked peptides, including the pGAPase refractory pyroglutamate-proline starting peptides. The hNaa50p specificity profile, delineated following multiple sequence alignment analysis using iceLogo (54) (Fig. 2A) revealed that hNaa50p was predominantly selective for peptides starting with leucine (697) or methionine (341); the P1 specificity accounting for 55 and 27% (or 82% in total) of all unique hNaa50p oligopeptide substrates identified. Besides being an N-end rule destabilizing residue (31, 55), leucine belongs to the class of residues of which the gyration radii precludes initiator Met-removal by methionine aminopeptidases (MAPs) (56, 57), and thus represents a physiologically irrelevant P1\(^\prime\)-residue for hNaa50p cotranslational acetylation. The unexpected high selectivity for leucine-starting peptides however might be explained by the fact that leucine and methionine share similar physicochemical characteristics (58, 59). And, given their similar side-chain hydrophobic nature, as well as preservation of favorable van der Waals interactions, leucine has been the preferred (if not exclusive) residue of choice for the substitution of methionine in proteins (60–62). Furthermore, given that N-terminal prolines inhibit N\(^\text{\textsuperscript{3}}\)-acetylation (8), the complete lack at position P1\(^\prime\) and P2\(^\prime\) and the very limited occurrence of Pro at P3\(^\prime\), indeed indicates the highly inhibitory potential of N-terminally positioned prolines on hNaa50p-activity. Medium-sized hy-
The specificity profile of recombinant hNaa10p—Similarly to hNaa50p, an maltose binding protein (MBP)-hNaa10p fusion protein was expressed in E. coli and the purified enzyme was incubated with a proteome-derived library of N-terminal peptides. Overall, 6,169 MS/MS spectra (65% of all spectra identified) belonged to 2,399 unique N-13C2-acetylated peptides. Surprisingly, the observed substrate specificity of the individual catalytic subunit hNaa10p does not correlate with the proposed specificity of the protein N-terminal acetyltransferase complex hNatA in which it predominantly resides. Isolated hNaa10p appears to favor peptides starting with acidic residues and more specifically Glu-starting N termini (Fig. 2B): 777 (32%) of all identified hNaa10p-acetylated substrate peptides start with Glu, whereas 287 (12%) and 250 (10%) carried an Asp or Glu at their P2’-position. Combined, these peptides account for 1250 (52%) of all peptides identified. Of further note is that Asp at P2’ (Asp is generally underrepresented at P1’ as only 71 (3%) of all unique peptides identified are Asp-starting peptides) is enriched in peptides not holding Glu at P1’. 84% of all P2’-Asp containing hNaa10p substrate peptides, indicating that having at least one acidic residue at P1’ (Glu) or P2’ (Asp) is highly preferred for isolated recombinant hNaa10p-mediated acetylation. In this respect, it is also noteworthy that 84 (3.5%) of the identified peptides start with a Glu-Glu motif. As for the remaining peptides, only 344 (14%) point to the proposed NatA-type specificity; i.e. starting with Ala (184), Cys (44), Gly (18), Ser (49), Val (37), or Thr (12). Of particular note is that Ser and Thr, being the preferred P1’ substrate of the human NatA complex, with a frequency of in vivo (partial) N-acetylation of over 99 and 92% (4), respectively, are here highly underrepresented (Fig. 2B). In general, Ala has a higher frequency of occurrence, especially at P2’ and P3’ (Fig. 2B). This observation hints to the fact that residues beyond P1’ might steer hNaa10p-substrate interaction. As observed for the hNaa50p study, proline is also inhibitory for N-acetylation by hNaa10p.

The specificity profile of hNatA—To assess the N-acetyltransferase activity of an endogenous NAT complex, and more in particular hNaa50p and hNaa10p in their native context, the activity of the immunoprecipitated endogenous hNaa15p-hNaa10p-hNaa50p complex was assayed. Because this NatA complex was immunoprecipitated by anti-hNaa15p, which was shown to effectively co-immunoprecipitate hNaa10p and hNaa50p (9, 15, 17), all the hNaa10p and hNaa50p present was stably bound to hNaa15p, and thus only genuine NatA complexes were assayed for as described above. In contrast to the high number of substrates identified when using recombinant enzymes, only 52 unique N-13C2-acetylated peptides were identified as hNatA substrates (Fig. 2C1). These results are probably indicative for the fact that, as compared with the recombinant enzyme preparation, far less enzyme was used (i.e. endogenous NAT complexes). Interestingly, the delineated NatA substrate specificity was mainly directed toward Ser-starting peptides (22 peptides, 43% of total) (Fig. 2C2) and Met- and Leu-starting peptides (22 or 43%) (Fig. 2C3), whereas only one Asp- and one Glu-starting peptide, i.e. the preferred recognition motif of recombinant hNaa10p (Fig. 2B), were identified. Taken together, our results let us discern two different types of N-acetylation specificities in the immunoprecipitated NatA complex, hinting to the fact that activities of both catalytic subunits present in the hNatA complex, hNaa10p and hNaa50p, were assayed for during our experiment. Additionally, the extended specificity profile of hNaa50p within the hNatA complex agrees very well with that of individual, recombinant hNaa50p because, besides the similar preference at P2’, acidic residues were found enriched from P3’ to P5’ (Figs. 2A and 2C3). Of further note is that 22 out of the 26 (85%) P2’-residues in Ser- or Ala-starting peptides are occupied by Ser (11), Ala (6), or Thr (5), representative for optimal NatA-type substrate N termini in vivo (4) (Fig. 2C2), and thus demonstrating that the in vitro specificity profile observed, can be extrapolated to the in vivo NatA-type substrate specificity (4).

hNaa10p and hNatA Acetylate Actin N Termi—We further wanted to pursue whether the observed activity of the hNaa10p catalytic subunit of NatA toward acidic N termini could be of physiological relevance. Of note is that very exceptionally, mature protein N termini start with an acidic amino acid, as acidic residues normally retain their initiator methionine. Actins from most eukaryotic species however undergo a unique N-terminal protein modification process, which has been shown to play important roles in the interaction of actin with several actin-binding proteins (63–68). N-terminal actin modifications, include the post-translational removal of the acetylated initiator methionine, in the case of β- and γ-actin by an unconventional MAP, and the cotranslational removal of the initiator methionine and post-translational removal of the N-terminal acetylated cysteine in the case of α-actin, leaving all of them with an acidic residue at their newly exposed N terminus (69–71). Final maturation of these N termini requires N-acetylation. However, this unconventional post-translational N-acetylation activity has so far remained uncharacterized. Therefore, a previously developed method based on RP-HPLC peptide separation, enabling the determination of kinetic constants and efficiency of N-acetylation was here used for studying the degree of actin peptide N-acetylation (16). Purified hNaa10p was incubated with various actin-derived, N-terminal-like peptides and acetyl-CoA, and product formation was followed for each of these peptides (Fig. 3A). In these experiments, the efficiency of N-
Acetylation correlated with the degree of in vivo N*-acetylation states of the respective substrate N termini given that the AVFAD motif represents a semioptimal substrate (derived from a partially acetylated in vivo substrate), whereas the SESSS motif is representative of a fully N*-acetylated protein. Further, the SPTPP-starting peptide representative of an in vivo unacetylated protein N terminus was here also found to remain unacetylated following incubation with purified hNaa10p (4). However, and in line with the substrate specificity determined from the hNaa10p peptide library screen, hNaa10p strongly preferred the acidic actin N termini over these well-characterized in vitro and in vivo substrates as actin N termini appear to be N*-acetylated about a 1000-fold better by hNaa10p. As such, these actin-derived N-terminal peptides represent by far the best hNaa10p in vitro substrate peptides identified to date. Another important issue is whether hNaa10p in the context of the endogenous NatA complex is capable of acetylating these actin N termini. As demonstrated above, the immunoprecipitated NatA complex preferred Ser besides Met and Leu-starting N termini. To this end, we analyzed the capacity of the immunoprecipitated hNatA complex to acetylate the actin-derived N-terminal peptides. The immunoprecipitated hNatA complex acetylated the acidic N terminus (EEEIA) two- to threefold better as compared with the established in vivo acetylated peptide SESSS (fully N*-acetylated N terminus in vivo), whereas on the other hand, SESSS is twofold more efficiently acetylated by the NatA complex as compared with the β-actin N terminus (DDDIA) (Fig. 3B). Consequently, both purified hNaa10p and the hNatA complex prefer the γ-actin N terminus over the known Ser-type of substrates. However, there is a dramatic specificity shift between purified hNaa10p and the hNatA complex as hNaa10p prefers Ser-starting peptides, whereas recombinant hNaa10p prefers acidic actin N termini. Further analyses demonstrated that isolated hNaa50p is unable to significantly acetylate the actin N termini (Fig. 3C). Thus, the NAT activity of the NatA complex toward actin N termini is solely a consequence of hNaa10p activity, and not hNaa50p and we therefore propose hNaa10p and/or hNatA as the post-translational actin N*-acyltransferase.

**A Major Fraction of NatA is not Associated With Ribosomes and a Minor Fraction of Cytosolic hNaa10p Exists Independent of the NatA Complex**—The substrate specificity results (Fig. 3) indicate that hNaa10p may act alone on acidic actin N termini. To address whether some cellular hNaa10p may exist independently of the NatA complex, we performed gel filtration analyses of A-431 cell homogenates. Both hNaa15p and indicated oligopeptide substrates (200 μM) at saturated levels of acetyl-CoA (500 μM) and incubated for 60 min at 37 °C in acetylation buffer. Values from negative control immunoprecipitations were subtracted from the NatA values to obtain specific activity values. C, Purified GST-hNaa50p (50 nm) was assayed as in A, but with an incubation time of 30 min.

![Figure 3](image-url)
A minor fraction of hNaa10p does not co-fractionate with hNaa15p. Human A-431 cells were homogenized and subjected to gel filtration using a Superdex-200 column. Fractions were collected and analyzed by SDS-PAGE and Western blotting using anti-hNaa10p and anti-hNaa15p. Fraction numbers are indicated above the lanes and standard proteins used to calibrate the gel filtration column are indicated below the lanes. Standard proteins include ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), and carbonic anhydrase (29 kDa). “Ctr” indicates internal total A-431 lysate control used to track the proteins of interest and to verify equal exposure of different gels run in parallel. Results shown are representative of three independent experiments.

In addition, the side-chains of lysine and cysteine are blocked by acetylation and carbamidomethylation respectively, which might alter NAT substrate recognition. Of note, as compared with Swiss-Prot, the general occurrence of modified cyteines after performing an LC-MS/MS-based quality control of the proteome derived peptide libraries revealed a general underrepresentation (data not shown). Further, because no information on the efficiency of N-acetylation can be obtained by our method, a previously developed method based on RP-HPLC was used to determine efficiencies of N-acetylation (16). However, in this respect it is noteworthy that in an independent peptide library screen for hNaa10p substrates, which made use of half of the peptide input material, although less substrate peptides were identified, the percentage of Glu- and, to a much lower extent, Asp-starting peptides increased to 70%, most likely reflecting the fact that Glu-starting peptides are much more efficiently N-acetylated as compared with the other identified peptideic substrates (data not shown).

Previous reports and the present study show that individual catalytic subunits inherently hold enzymatic activity, demonstrating that the substrate specificity observed for intact NAT complexes is at least partially contained when only studying their catalytic subunits (28). In this regard, hNaa50p was reported to display Met-Leu N-acetylation activity, whereas additionally allowing small, hydrophobic as well as negatively
Delineating the Specificity Profile of N\(^{\alpha}\)-acetyltransferases

**Fig. 6. Overview of the hNatA, hNatE, and individual hNaa10p and hNaa50p enzymatic activities.** The ribosome-bound subunits hNaa10p and hNaa15p combine to form the functional hNatA complex and cotranslationally acetylate nascent polypeptides (e.g. polypeptide with an N-terminal serine). hNaa50p, responsible for the observed NatE activity, may physically associate with hNaa10p and hNaa15p of the hNatA complex. NatE activity is mainly directed toward MK, MM, MA, and MI starting N termini. Nonpolysomal bound hNaa10p and hNaa50p might be responsible for the post-translationally N\(^{\alpha}\)-acetylation of acidic actin N termini and other hNaa50p-type substrate N termini respectively, independent of the NatA complex. HYPK is stably associated with the NatA complex and might contact with nascent polypeptides. ACTG, \(\gamma\)-actin; ACTB, \(\beta\)-actin; SS, small ribosomal subunit; LG, large ribosomal subunit.

charged residues at P3’ substrate positions (16). In this study, the Met-Leu substrate preference was verified, and additionally, specificities directed toward Met-Lys, Met-Met, and Met-Ala starting N termini were observed. Because only about 0.12% of all Arg-C generated peptides are estimated to start with a methionine, the nearly 27% of Met-starting hNaa50p substrate sequences identified here, implicate a more than 200-fold selective enrichment. Therefore, in vitro, Met might very well be preferred over Leu at P1’, especially because Leu at P1’-positions (55% of all peptides identified) only represents a 30-fold enrichment given that 1.6% of all Arg-C generated peptides start with a Leu. In contrast to the results previously reported (16), we could not observe a preference of Pro at P4’. Nevertheless, and in contrast to the zero tolerance at P1’ and P2’ and very limited tolerance at P3’, nearly 6% of the P4’-positions were occupied by a proline in the hNaa50p peptide substrates, indicating that this residue is tolerated at P4’, but not preferred. The lack of significant activity of the NatA-complex toward the MLGP-polypeptide (as was shown for purified hNaa50p) might be explained by the observation that subtil changes in P2’-substrate specificity were observed when assaying hNaa50p alone opposed to when it is present in its endogenous complex (Fig. 2A versus Fig. 2C3). Nevertheless, the extended specificity profile from P3’ to P5’ was nearly indistinguishable. Because the N\(^{\alpha}\)-acyetyltransferase(s) responsible for Met-Lys, Met-Ala, and Met-Met starting N termini, N termini often found to be N\(^{\alpha}\)-acylated in vivo in human cells, are not yet characterized, our results indicate hNaa50p to be a likely candidate for acetylating these protein N termini. In fact, its activity toward Met-Leu starting peptides is shared with the catalytic subunit Naa30p of NatC, and thus points to substrate redundancy among NATs.

Interestingly, the specificity shift between purified hNaa10p and the hNatA complex toward a relative preference of hNatA for Ser besides Met-starting peptides, and of the hNaa10p for acidic (actin) N termini, may reflect an in vivo activity of hNaa10p to post-translationally acetylate actin N termini independent of the NatA complex. In support of this, our gel filtration assays demonstrated that a fraction of cellular hNaa10p exists independently of hNaa15p and the NatA complex (Fig. 4). In this respect it is also noteworthy that a significant portion of the NAT subunits, hNaa10p, hNaa50p, and hNaa15p, can be detected in the nonpolysomal bound fraction, indicative for the fact that they may additionally serve other purposes, alone or in complex, or allow for different substrate preferences of the enzyme (Fig. 5). An interesting observation is that hNaa15p (named Tubedown in this study) colocalizes with actin fibers and specifically interacts with the actin-binding protein cortactin in endothelial cells (72). This places hNaa15p and possibly the hNatA complex in close proximity to actins which may facilitate post-translational N-terminal acetylation of actin. Because functional roles for actin N\(^{\alpha}\)-acetylation have been demonstrated in yeast and fruit fly, identifying the actin-NAT is important. The in vitro data presented here strongly imply that hNaa10p/hNatA is a very likely actin-NAT candidate, especially bearing in mind that none of the other known human NAT significantly acetylate the actin N termini in vitro (Arnesen et al., unpublished data). However, because of the lack of KO models and viewing the fact that we previously demonstrated that despite a significant hNatA knockdown (i.e. 95% reduction of hNaa10p expression), solely a partial loss in N-terminal acetylation was observed for proteins displaying suboptimal hNatA substrate sequences in vivo (4), the in vivo role of NatA/hNaa10p in actin function of
higher eukaryotic species awaits functional analyses. An overview illustrating the known and postulated Nα-acetylating activities of the hNatA-complex, hNatE and individual catalytic subunits is shown in Fig. 6.

Acknowledgments—P.V.D. is a Postdoctoral Fellow of the Research Foundation - Flanders (FWO-Vlaanderen). Nina Glomenne is thanked for technical assistance.

* We further acknowledge support of research grants from the Fund for Scientific Research - Flanders (Belgium) (project numbers G.0042.07 and G.0440.10), the Concerted Research Actions (project BOF7/GOA/012) from the Ghent University, the Inter University Attraction Pole (IUAP06), the Norwegian Research Council (Grant 197136 to TA), and the Norwegian Cancer Society (to JRL and TA).

This article contains supplemental Fig. S1 and Table S1.

** To whom correspondence should be addressed: Department of Medical Protein Research, Flanders Interuniversity Institute for Biotechnology, Ghent University, A. Baertsoenkaai 3, B9000 Ghent, Belgium. Tel.: +32-926-49274; Fax: +32-926-49496; E-mail: kris.gevaert@vib.ugent.be.

‡‡ These authors share senior co-authorship.

REFERENCES

1. Polevoda, B., and Sherman, F. (2003) N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. *J. Mol. Biol.* **325**, 595–622

2. Gautschl, M., Just, S., Mun, A., Rosa, S., Rücknagel, P., Dubaqué, Y., Ehrenhofer-Murray, A., and Rospert, S. (2003) The yeast Nα-(acyl)-transferase Nαta is quantitatively anchored to the ribosome and interacts with nascent polypeptides. *Mol. Cell. Biol.* **23**, 7403–7414

3. Helbig, A. O., Gauci, S., Rajimakers, R., van Breukelen, B., Sliper, M., Mohammed, S., and Heck, A. J. (2010) Profiling of N-acetylated protein termini provides in-depth insights into the N-terminal nature of the proteome. *Mol. Cell. Proteomics* **9**, 928–939

4. Arnesen, T., Van Damme, P., Polevoda, B., Helsens, K., Evjenth, R., Coletar, N., Varhaug, J. E., VanDerKerkhove, J., Lillehaug, J. R., Sherman, F., and Gevaert, A. (2009) Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 8157–8162

5. Lee, F. J., Lin, W. W., and Smith, J. A. (1989) Nα-acetyltransferase deficiency alters protein synthesis in Saccharomyces cerevisiae. *FEBS Lett.* **256**, 130–142

6. Polevoda, B., and Sherman, F. (2000) Nαla -terminal acetylation of eukaryotic proteins. *J. Biol. Chem.* **275**, 36479–36482

7. Driessen, H. P., de Jong, W. W., Tesser, G. I., and Bloemendal, H. (1985) The mechanism of N-terminal acetylation of proteins. *CRC. Crit. Rev. Biochem.* **18**, 281–325

8. Goetze, S., Qei, E., Mosimann, C., Staes, A., Gerrits, B., Roschitzki, B., Mohanty, S., Niederer, E., Laczko, E., Timmerman, E., Lange, V., Hafen, E., Aebersold, R., VanDerKerkhove, J., Basler, K., Ahrens, K., Gevaert, K., and Brunner, E. (2009) Identification and functional characterization of N-terminal protein acetylations in Drosophila melanogaster. *J. Proteome Res.* **6**, 4634–4465

9. Arnesen, T., Anderson, D., Torsvik, J., Halseth, H. B., Varhaug, J. E., and Martinho, R. G. (2008) Differential requirements of a mitotic acetyltransferase in somatic and germ line cells. *J. Cell. Biol.* **177**, 197–206

10. Arnesen, T., Anderson, D., Torsvik, J., Halseth, H. B., Varhaug, J. E., and Lillehaug, J. R. (2006) Cloning and characterization of the human Nα-terminal acetyltransferase complex. *J. Biol. Chem.* **281**, 31122–31129

11. Arnesen, T., Starheim, K. K., Van Damme, P., Evjenth, R., Dinh, H., Betts, M. J., Ryningen, A., VanDerKerkhove, J., Gevaert, K., and Anderson, D. (2010) The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntington aggregation. *Mol. Cell. Biol.* **30**, 1898–1909

12. Starheim, K. K., Gromyk, V., Sliper, M., Varhaug, J. E., and Arnesen, T. (2009) Composition and biological significance of the human N-terminal acetyltransferases. *MBC Proc.* **3**, S3

13. Arnesen, T., Thompson, P. R., Varhaug, J. E., and Lillehaug, J. R. (2008) The protein acetyltransferase ARD1: a novel cancer drug target? *Curr. Cancer Drug Targets*. **8**, 545–553

14. Chun, K. H., Cho, S. J., Choi, J. S., Kim, S. H., Kim, K. W., and Lee, S. K. (2007) Differential regulation of splicing, localization and stability of mammalian ARD1235 and ARD1225 isoforms. *Biochem. Biophys. Res. Commun.* **353**, 18–25

15. Lee, C. F., Ou, D. S., Lee, S. B., Chang, L. H., Li, Y. S., Upadhyay, A. K., Cheng, X., Wang, Y. C., Hsu, H. S., Hisao, M., Wu, C. W., and Juan, L. J. (2010) Naa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. *J. Clin. Invest.* **120**, 2920–2930

16. Chu, C. W., Hou, F., Zhang, J., Fu, P., Loko, A. V., Kirkpatrick, D. S., Jackson, P. K., Zhao, Y., and Zou, H. (2010) A novel acetylation of (beta)-tubulin by San modulates microtubule polymerization via down-regulating tubulin incorporation. *Mol. Biol. Cell.* **21**, 448–456

17. Lim, J. H., Park, J. W., and Chun, Y. S. (2006) Human arrest defective 1 acetylases and activates beta-catenin, promoting lung cancer cell proliferation. *Cancer Res.* **66**, 10677–10682

18. Dongmeier, W., Mohammed, S., Breukelen, B. V., Krijgsveeld, J., and Heck, A. J. (2007) Targeted Analysis of Protein Termini. *J. Proteome Res.* **6**, 4634–4465

19. Helbig, A. O., Gauci, S., Rajimakers, R., van Breukelen, B., Sliper, M., Mohammed, S., and Heck, A. J. (2010) Perturbation of the yeast Nα-acetyltransferase Nαta induces elevation of protein phosphorylation levels. *MBC Genomics* **11**, 685

20. Starheim, K. K., Arnesen, T., Gromyk, D., Ryningen, A., Varhaug, J. E., and Lillehaug, J. R. (2008) Identification of the human Nα-(acyl)-transferase complex B (hNatB): a complex important for cell-cycle progression. *Biochem. J.* **415**, 325–331

21. Starheim, K. K., Gromyk, D., Evjenth, R., Ryningen, A., Varhaug, J. E., Lillehaug, J. R., and Arnesen, T. (2009) Knockdown of human Nα-terminal acetyltransferase complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization. *Mol. Cell. Biol.* **29**, 3569–3581

22. Urbanickova, M., and Hitchcock-DeGregori, S. E. (1994) Requirement of amino-terminal modification for striated muscle alpha-tropomyosin function. *J. Biol. Chem.* **269**, 24310–24315

23. Behnke, R. P., Panic, B., Whyte, J. R., and Munro, S. (2004) Targeting of the Arf-like GTPase Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p. *Nat. Cell. Biol.* **6**, 405–413

24. Hwang, C. S., Shemorry, A., and Varshavsky, A. (2010) N-terminal acetylation of cellular proteins creates specific degradation signals. *Science* **327**, 973–977
32. Polevoda, B., Arnesen, T., and Sherman, F. (2009) A synopsis of eukaryotic Nα-terminal acetyltransferases: nomenclature, subunits and substrates. *BMC Proc.* 3, S2

33. Arnesen, T., Betts, M. J., Pandino, F., Libeles, D. A., Anderson, D., Caro, J., Kong, X., Varhaug, J. E., and Lilleaug, J. R. (2006) Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase. *BMC Biochem.* 7, 13

34. Arnesen, T., Gromyko, D., Kagabo, D., Betts, M. J., Starheim, K. K., Varhaug, J. E., Anderson, D., and Lilleaug, J. R. (2009) A novel human NAT α Nα-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1). *BMC Biochem.* 10, 15

35. Arnold, R. J., Polevoda, B., Reilly, J. P., and Sherman, F. (1999) The action of N-terminal acetyltransferases on yeast ribosomal proteins. *J. Biol. Chem.* 274, 37035–37040

36. Polevoda, B., Norbeck, J., Taksikura, H., Blomberg, A., and Sherman, F. (1999) Identification and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae. *EMBO J.* 18, 6155–6168

37. Kimura, Y., Takaoka, M., Tanaka, S., Sassa, H., Tanaka, K., Polevoda, B., Sherman, F., and Hirano, H. (2000) Nαpalp-αacetolylating and proteinolytic activity of the yeast S G proteasome. *J. Biol. Chem.* 275, 4635–4639

38. Boucherle, H., Sagliocco, F., Joubert, R., Maillet, I., Labarre, J., and Perrot, M. (1996) Two-dimensional gel protein database of Saccharomyces cerevisiae. *Electrophoresis* 17, 1683–1699

39. Staes, A., Van Damme, P., Helsens, K., Demol, H., Vandekerckhove, J., and Gevaert, K. (2008) Improved recovery of proteome-informative, protein N-terminal peptides by combined fractional diagonal chromatography (COFRADIC). *Proteomics* 8, 3362–3370

40. Van Damme, P., Van Damme, J., Demol, H., Staes, A., Vandekerckhove, J., and Gevaert, K. (2009) A review of COFRADIC techniques targeting protein N-terminal acetylation. *BMC Proc.* 3, S6

41. Maier, R. H., Maier, C. J., Rid, R., Hintner, H., Bauer, J. W., and Onder, K. (2010) Epitope mapping of antibodies using a cell array-based polypeptide library. *J. Biolum. Biophot.* 5, 148–162

42. Beutling, U., Staeding, K., Stradal, T., and Frank, R. (2008) Large-scale analysis of protein-protein interactions using cellulose-bound peptide arrays. *Adv Biochem. Eng. Biotechnol.* 110, 115–152

43. Schutkowski, M., Reineke, U., and Reimer, U. (2005) Peptide arrays for peptide deformylase through the determination of substrate specificity for peptide deformylase through the terminary positional proteomics for screening substrates of endo- and exo-proteases. *Nat. Biotechnol.* 23, 943–948

44. Bordo, D., and Argos, P. (1991) Suggestions for “safe” residue substitutions in site-directed mutagenesis. *J. Mol. Biol.* 217, 721–729

45. Sutoh, K., and Hatanou, S. (1996) Actin-fragmin interactions as revealed by atomic positional proteomics for screening substrates of endo- and exo-proteases. *Annu. Rev. Biochem.* 65, 615–635

46. Duy, Y., Higashida, M., and Kidou, S. (1987) Plasma-gelsolin-binding sites on the actin sequence. *J. Biol. Chem.* 262, 9430–9436

47. Sheff, D. R., and Rubenstein, P. A. (1992) Isolation and characterization of the rat liver actin N-acetylaminopeptidase. *J. Biol. Chem.* 267, 102–106

48. Doi, Y., Higashida, M., and Kidou, S. (1987) Plasma-gelsolin-binding sites on the actin sequence. *J. Biol. Chem.* 262, 9430–9436

49. Adams, S., DasGupta, G., Chalovich, J. M., and Reisler, E. (1990) Immunochemical evidence for the binding of caldesmon to the NH2-terminal segment of actin. *J. Biol. Chem.* 265, 16562–16567

50. DasGupta, G., and Reisler, E. (1991) Nucleotide-induced changes in the interaction of myosin with heavy chains of actin. *Biochemistry* 30, 9961–9966

51. Cook, R. K., Blake, W. T., and Rubenstein, P. A. (1992) Removal of the amino-terminal acidic residues of yeast actin. *Biochem. Biophys. Res. Commun.* 18, 438–440

52. Sheff, D. R., and Rubenstein, P. A. (1992) Isolation and characterization of the rat liver actin N-acetylaminopeptidase. *J. Biol. Chem.* 267, 9430–9436

53. Paradies, H., Islam, T., Tucker, C., Tock, S., Koubi, S., and Gendron, R. L. (2008) Tissue-resident or tissue-derived factors stimulate the rat liver actin N-acetylaminopeptidase. *Biochem. Biophys. Res. Commun.* 353, 754–757

54. Sutoh, K., and Hatanou, S. (1996) Actin-fragmin interactions as revealed by chemical cross-linking. *Biochemistry* 25, 435–440

55. Cook, R. K., Blake, W. T., and Rubenstein, P. A. (1992) Removal of the amino-terminal acidic residues of yeast actin. *Biochem. Biophys. Res. Commun.* 18, 438–440

56. Sheff, D. R., and Rubenstein, P. A. (1992) Isolation and characterization of the rat liver actin N-acetylaminopeptidase. *J. Biol. Chem.* 267, 9430–9436

57. Paradies, H., Islam, T., Tucker, C., Tock, S., Koubi, S., and Gendron, R. L. (2008) Tissue-resident or tissue-derived factors stimulate the rat liver actin N-acetylaminopeptidase. *Biochem. Biophys. Res. Commun.* 353, 754–757

58. Martens, L., Hermjakob, H., Jones, P., Adamkiew, M., Taylor, C., Stases, D., Gevaert, K., Vandekerckhove, J., and Apeblin, R. P. (2005) PRIDE: the proteomics identifications database. *Proteomics* 5, 3537–3545

In order to cite this article properly, please include all of the following information: Van Damme, P., Evjen, R., Foyen, H., Demeyer, K., De Bock, P.-J., Lilleaug, J. R., Vandekerckhove, J., Arnesen, T., and Gevaert, K. (2011) Proteome-derived Peptide Libraries Allow Detailed Analysis of the Substrate Specificities of Nα-acetyltransferases and Point to hNaa10p as the Post-translational Actin Nα-acetyltransferase. *Mol. Cell. Proteomics* 10(5):M110.004580. DOI: 10.1074/mcp.M110.004580.